Merck, Drug Prices & Medicare Spending

Merck manufactures 18 drugs tracked by Medicare Part D with total spending of $13.7B.

Drugs Tracked

$13.7B

Medicare Spending

$110.29

Avg Cost/Claim

89%

Have Generics

Merck Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Keytruda	Pembrolizumab	$18,176.00	$7.2B	+28.6%	No
2	Januvia	Sitagliptin	$219.00	$2.7B	-12.3%	No
3	Janumet	Sitagliptin/Metformin	$180.00	$876.0M	-8.6%	Yes
4	Isentress	Raltegravir	$2,452.00	$456.0M	-14.2%	Yes
5	Dificid	Fidaxomicin	$1,391.00	$345.0M	+8.4%	Yes
6	Zetia	Ezetimibe	$21.00	$298.0M	-38.7%	Yes
7	Losartan	Losartan Potassium	$9.00	$234.0M	-28.4%	Yes
8	Noxafil	Posaconazole	$2,721.00	$234.0M	+4.2%	Yes
9	Steglatro	Ertugliflozin	$144.00	$178.0M	-12.3%	Yes
10	Verquvo	Vericiguat	$511.00	$178.0M	+56.3%	Yes
11	Vytorin	Ezetimibe/Simvastatin	$58.00	$145.0M	-34.2%	Yes
12	Singulair	Montelukast	$12.00	$145.0M	-38.4%	Yes
13	Montelukast	Montelukast Sodium	$13.00	$145.0M	-28.6%	Yes
14	Simvastatin	Simvastatin	$7.00	$123.0M	-34.6%	Yes
15	Finasteride	Finasteride	$10.00	$89.0M	-18.4%	Yes
16	Alendronate	Alendronate Sodium	$14.00	$89.0M	-28.6%	Yes
17	Dorzolamide-Timolol	Dorzolamide/Timolol	$36.00	$89.0M	-18.4%	Yes
18	Rizatriptan	Rizatriptan Benzoate	$27.00	$67.0M	-18.6%	Yes

Frequently Asked Questions

Merck manufactures 18 drugs tracked by Medicare Part D, with total annual spending of $13.7B.

Keytruda (Pembrolizumab) is the most expensive at $18,176.00 per claim.

16 of 18 Merck drugs (89%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

The this entity record above pulls directly from CMS Medicare Part D Drug Spending data. What follows is the per-entity context — how this entity sits in the broader U.S. Medicare prescription-drug pricing distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.